Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: Results from a phase 1/2 multi-dose study of VGA039 in patients with von Willebrand disease

ASH 2025 ABSTRACT #308 The post Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: Results from a phase 1/2 multi-dose study of VGA039 in patients with von Willebrand disease appeared first on STAR Therapeutics .